Gynecologic Oncology Reports (Dec 2022)

Nivolumab for malignant transformation of ovarian mature cystic teratoma

  • Kayoko Yoshimura,
  • Koji Yamanoi,
  • Masashi Kanai,
  • Asuka Okunomiya,
  • Yusuke Sagae,
  • Masumi Sunada,
  • Mana Taki,
  • Masayo Ukita,
  • Yoshitsugu Chigusa,
  • Akihito Horie,
  • Ken Yamaguchi,
  • Junzo Hamanishi,
  • Sachiko Minamiguchi,
  • Noboru Yamamoto,
  • Manabu Muto,
  • Masaki Mandai

Journal volume & issue
Vol. 44
p. 101115

Abstract

Read online

Mature cystic teratoma of the ovary (MCT) occasionally undergoes malignant transformation (MT) that is resistant to chemotherapy and has a poor prognosis. We experienced a case of clinically aggressive MCT-MT that invades surrounding organs and tissues. Although tumor was resected entirely, a rapid tumor recurrence occurred during postoperative chemotherapy (paclitaxel + ifosfamide + cisplatin). The results of comprehensive genomic profiling test performed early in the postoperative period showed a high tumor mutational burden of 23 mutations/Mb. Treatment with nivolumab monotherapy has promptly been initiated and has been very successful for more than one year.

Keywords